Digital dilemma in UK’s life sciences job market
Pharmaceutical Technology
SEPTEMBER 8, 2023
In this issue: Digital jobs in UK life sciences, generative AI changes drug discovery, and how robotics is impacting gene therapy manufacturing.
Sartorius upscales gene therapy prowess with $2.6bn Polyplus acquisition
Pharmaceutical Technology
APRIL 3, 2023
The deal will see Polyplus join the German life science group’s portfolio allowing the latter to leverage expertise in transfection reagents and plasmid DNA for gene therapy. Polyplus, based in Strasbourg, France, produces key components in the production of viral vectors used in cell and gene therapies.
Gene Therapy 
246
246 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
New facility boosts UK’s cell and gene therapy manufacturing capacity
Pharmaceutical Technology
MARCH 10, 2023
On 10 March, the National Health Service Blood and Transplant (NHSBT) opened a new Clinical Biotechnology Centre (CBC) with the aim of improving the UK’s ability to develop and manufacture cell and gene therapies. The NHSBT hopes the CBC will increase the UK’s competitiveness within the market.
Gene Therapy 264
264 
GSK and Wave Life Sciences partner to develop oligonucleotide therapeutics
Pharmaceutical Technology
DECEMBER 14, 2022
GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. On completion of the first-in-patient clinical trial by Wave, GSK will be in charge of the development and marketing works. By Cytiva Thematic.
Life Science 162
162 
Life Science Trends for 2023 – Xtalks Life Science Podcast Ep. 91
XTalks
JANUARY 4, 2023
In this episode, Ayesha talked about some of the trends to look out for in the life sciences in 2023. Read the full article here: 4 Life Sciences Trends for 2023. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Life Science 52
52 
Merck and Synplogen to develop viral vector gene therapies
Pharmaceutical Technology
DECEMBER 14, 2022
Merck and Synplogen have signed a non-binding Memorandum of Understanding (MoU) to expedite the development and manufacturing of viral vector-based gene therapy applications. The firms intend to merge their expertise to provide simplified viral vector gene therapy development, production and testing in Japan.
Gene Therapy 130
130 
Bespoke Gene Therapy Consortium Selects 8 Rare Diseases for Clinical Trial Portfolio
XTalks
MAY 17, 2023
The Foundation for the National Institutes of Health (FNIH) announced this week that the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) has selected eight rare diseases for its clinical trial portfolio. As such, rare disease patients and their families often face little hope for effective treatments.
Gene Therapy 98
98 
Guide to using AAV vectors in gene therapy
Drug Discovery World
FEBRUARY 8, 2024
In 2023, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.
Gene Therapy 59
59 
4 Life Sciences Trends for 2023
XTalks
DECEMBER 29, 2022
The life sciences and healthcare are among the biggest industries globally, and their significance was particularly highlighted during the past couple of years by the COVID-19 pandemic. Given the hyperfocus on the life sciences thanks to COVID, consumers appear to be more autonomous and vocal about their medical demands and choices.
Life Science 52
52 
Guide to using AAV vectors in gene therapy
Drug Discovery World
OCTOBER 3, 2023
Earlier this year, DDW hosted a webinar, ‘A comprehensive guide to using adeno-associated virus (AAV) vectors in gene therapy’, supported by Azenta Life Sciences. AAV is optimal for gene therapy due to its efficiency and safety in humans; however, AAV processes can present obstacles for researchers.
Gene Therapy 52
52 
Lyfgenia and Casgevy Become First FDA-Approved Gene Therapies for Sickle Cell Disease
XTalks
DECEMBER 13, 2023
The US Food and Drug Administration (FDA) has approved the first gene therapies for the treatment of sickle cell disease, approving two on the same day. Both gene therapies are approved for individuals 12 years of age and older with sickle cell disease. How do Casgevy and Lyfgenia Work? million after discounts.
Gene Therapy 98
98 
Challenges of managing PHI & PII Data in Life Sciences and How AI/ML can help
Cloudbyz
SEPTEMBER 10, 2023
The challenge of managing and securing sensitive data, including PHI and PII, is significant for life sciences organizations. Additionally, the consequences of data breaches can be severe for life sciences organizations. The challenge is further compounded by the need for fast and accurate analysis of data.
Life Science 91
91 
Can vertical AI advance cell and gene therapies?
Drug Discovery World
DECEMBER 8, 2023
Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The cell and gene therapy industry is no exception to this digital transformation. Here’s what this means for pharmaceutical leaders and patients.
Gene Therapy 64
64 
Cell and Gene Therapy Catapult opens new Scottish laboratories
Drug Discovery World
JUNE 12, 2023
It is the UK’s first specifically designed accessible laboratory for the cell and gene therapy industry. This investment in Scotland builds upon CGT Catapult’s existing work supporting emerging advanced therapy clusters in the UK, with its Manufacturing Innovation Centres in Stevenage, Hertfordshire and Braintree, Essex.
Gene Therapy 52
52 
10 Key Learnings from Successful Cellular and Gene Therapy Trials for Rare Diseases
XTalks
APRIL 24, 2023
Awareness of rare diseases is growing, and with a better understanding of the pathophysiology of many rare diseases, innovative treatment options are emerging, like gene therapies that can treat the root cause of rare genetic diseases and potentially provide long-term symptom relief, or even a definitive cure.
Gene Therapy 95
95 
Top Life Science News and Trends in 2023 at Xtalks
XTalks
DECEMBER 20, 2023
In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.
Life Science 59
59 
Can characterisation industrialise cell and gene therapy?
Drug Discovery World
MARCH 16, 2023
The cell and gene therapy (CGT) market is rapidly expanding, and projections suggest it will reach over $90B by 2023. Challenges of cell and gene therapy manufacturing Compared to traditional biologics, CGTs are living drugs, making their development and manufacturing substantially more complex.
Gene Therapy 52
52 
Can Europe become a major player in cell and gene therapy?
Drug Discovery World
NOVEMBER 24, 2022
With European life sciences R&D investment at a 20-year low, biopharmaceutical associations and MEPs are calling on the EU to modernise its policies. DDW’s Diana Spencer asks what will be needed for Europe to compete in the growing global market for advanced therapies. . Developing world class innovation hubs.
Gene Therapy 98
98 
Cell & Gene Therapy Product Development: How Can You Build a Successful Partnership with Your CRO’s Project Manager?
XTalks
JUNE 8, 2023
Over the past few years, there has been a significant expansion in the cell and gene therapy landscape, with an increasing number of therapies entering clinical trials and receiving regulatory approvals. “I think if we all go into these relationships with this mindset, we’ll achieve great things together.”
Gene Therapy 98
98 
Roctavian Becomes First Gene Therapy for Severe Hemophilia A to Get FDA Nod
XTalks
JUNE 30, 2023
It’s been a big week for cell and gene therapy approvals in the US, including a much-awaited approval for one to treat hemophilia A, the most common form of hemophilia. BioMarin said the majority of patients who received Roctavian received corticosteroids to suppress the immune system for the gene therapy to be effective and safe.
Gene Therapy 98
98 
Pharmaron’s Liverpool based gene therapy CDMO wins UK government grant
BioPharma Reporter
MARCH 30, 2023
Pharmaron Beijing Co Ltd says its Liverpool, UK based gene therapy CDMO has obtained a grant from the UK governmentâs life sciences innovation manufacturing fund (LSMIF) to expand its facilities.
Gene Therapy 52
52 
Race is on to claim share of biomanufacturing market
Pharmaceutical Technology
NOVEMBER 23, 2022
Innovations in biotechnology are advancing the biopharmaceutical market, enabling the treatment of complex diseases with next-generation therapeutics synthesised or extracted from a biological source. With around 35,000 employees, the broader life sciences sector is one of Hamilton’s largest industries.
Marketing 130
130 
Understanding the future roadmaps of cell and gene therapy
Drug Discovery World
MAY 23, 2023
DDW’s Megan Thomas caught up with George White , General Manager, Product Management, Cell & Gene Therapy at Cytiva, to learn more about the company’s insight into the CGT market. We’re seeing a drive towards the allogeneic market with more progressing into clinical trials.
Gene Therapy 52
52 
Transcending expectations for cell & gene therapy development
Drug Discovery World
JULY 11, 2022
David Lewandowski, Business Director of Cell & Gene Therapy at Azenta Life Sciences, explains how efficient sample management can help to work efficiently and bring therapies to market faster. It has been estimated that by 2025 the FDA will be approving 10 to 20 cell and gene therapy products per year 2.
Gene Therapy 52
52 
Cell and gene therapies: Opportunities for innovation
Drug Discovery World
SEPTEMBER 6, 2022
In recent years the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are not only transforming the way diseases are treated but are also aiming to cure entirely new patient populations. ViaCyte, Beam, and Verve are all due to begin gene editing trials this year.
Gene Therapy 52
52 
No sign of stopping: The rise of cell and gene therapy
Drug Discovery World
MAY 22, 2023
Ryan Leahy , a science communication expert in cell and gene therapy, at Phacilitate, says there is a lot to celebrate but also much to assess, question and challenge in this sector. Its subsequent success with approval in the US shows us that some drugs will be unavailable to some markets and patients for now.
Gene Therapy 52
52 
Interview with Definitive Healthcare’s VP, Head of Healthcare Consulting, Manu Garg, About Healthcare Commercial Intelligence — Xtalks Life Science Podcast Ep. 103
XTalks
MARCH 29, 2023
As new drug development is increasingly focused on targeted therapies for rare diseases and other indications with limited patient pools, healthcare commercial intelligence can help companies find their target market and help direct resources. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Life Science 52
52 
The Unprecedented Growth of Cell and Gene Therapy (2021)
Cloudbyz
MAY 19, 2021
Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. The gene therapy market reported its first market approvals back in 2017 and the evolution has been extensive ever since.
Gene Therapy 52
52 
Teknova unveils new manufacturing facility for high-quality reagents
BioPharma Reporter
AUGUST 14, 2023
Teknova, a producer of life science reagents, has opened a new GMP-certified production facility which it claims will enable bioprocessing and gene therapy companies to get into the clinic faster.
Reagent 98
98 
The challenges and trends of cell & gene therapies
Drug Discovery World
SEPTEMBER 6, 2022
DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.
Gene Therapy 52
52 
Fujifilm to acquire Shenandoah Biotechnology
BioPharma Reporter
MARCH 22, 2022
Fujifilm Irvine Scientific, Inc, has announced the acquisition of Shenandoah Biotechnology, a company supplying recombinant proteins to the drug discovery, life science research, and cell and gene therapy markets.
Gene Therapy 98
98 
Donaldson acquires Univercells Technologies for €136 million
BioPharma Reporter
JULY 3, 2023
Donaldson, a provider of filtration products and solutions, has acquired Univercells Technologies, a producer of biomanufacturing solutions for cell and gene therapy research, development, and commercial manufacturing, to broaden its life sciences reach.
Gene Therapy 97
97 
Novartis’ $2 Million Gene Therapy Zolgensma Shows ‘Remarkable’ Results and Offers Hope for Children with SMA
XTalks
JUNE 8, 2021
Novartis’ Zolgensma (onasemnogene abeparvovec) gene therapy has been making significant strides as of late, including dosing of the first Spinal Muscular Atrophy (SMA) patient with the treatment in the UK last week. Prior to Zolgensma, treatments could only help manage symptoms and attempt to improve quality of life.
Gene Therapy 110
110 
FDA Approves Gene Therapy Adstiladrin for the Treatment of Bladder Cancer
XTalks
DECEMBER 27, 2022
Adstiladrin is an adenoviral vector-based gene therapy that is non-replicating, so it cannot multiply in human cells. XTALKS WEBINAR: Importance of Early Integrated Evidence Strategy for Cell & Gene Therapies. How Does the Gene Therapy Adstiladrin Work? The Clinical Trial that Led to the Approval.
Gene Therapy 52
52 
16th Annual Life Sciences Trade and Channel Strategies
Drug Channels
OCTOBER 19, 2020
16th Annual Life Sciences Trade and Channel Strategies. December 1-3, 2020 | Virtual Event www.informaconnect.com/trade-channel. Get ready to hit the ground running in 2021 by closing out the year at Trade and Channel 2020 ! Channel Strategy for First Medical Product – A Look at Channel Considerations for Pharmacy vs.
Life Science 52
52 
HEOR and Market Access Strategies in Today’s Drug Development Landscape – Insights from AstraZeneca’s Dr. Heather McDonald
XTalks
OCTOBER 4, 2023
Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.
Marketing 105
105 
16th Annual Life Sciences Trade and Channel Strategies
Drug Channels
NOVEMBER 8, 2020
16th Annual Life Sciences Trade and Channel Strategies. That’s why the life science industry’s top experts will come together virtually on December 1-3 at Trade and Channel 2020. December 1-3, 2020 | Virtual Event www.informaconnect.com/trade-channel. Stuart Parker, Senior Director, Trade Relations, Mayne Pharma And more!
Life Science 52
52 
Sensorion and Novasep Announce Signature of a Gene Therapy Product Development and Manufacturing Agreement
The Pharma Data
OCTOBER 26, 2020
The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Sensorion is currently advancing two preclinical gene therapy programs conducted under a broad multi-program research partnership with the Genetics and Physiology of Hearing Unit at Institut Pasteur (Paris).
Gene Therapy 52
52 
Changing Faces: agency, consultant, and investor hires from November 2022
pharmaphorum
DECEMBER 14, 2022
Healthcare commercial services agency Eversana announced that Sy Pretorius (as pictured), a 25-year life sciences veteran, will join the company as chief operating officer and president of outsourced solutions. November saw the launch of a new private equity team in life sciences at J.P. Eversana taps new COO.
Life Science 98
98 
Europe: Where is the drug discovery innovation?
Drug Discovery World
MAY 6, 2024
Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. Europe is traditionally a life sciences powerhouse, with a strong tradition in pharmaceutical discovery. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany.
Drugs 59
59 
Under the microscope: Zoning in on the CGT sector
Drug Discovery World
MAY 24, 2023
IB Communications’ CEO Michelle Boxall explains why there are two sides to the cell and gene therapy coin. With 2023’s financial outlook and predictions for the CGT market, there are two sides to this coin. The life science sector has come a long way from a simple binary choice of IPO or sale.
Gene Therapy 52
52 
Buoyant UK biotech sector secures £1.8bn investment in 2023
Drug Discovery World
JANUARY 25, 2024
The UK’s life sciences and biotech sector showed resilience in 2023, securing £1.8 ($2.2) This follows another BIA report in January 2024, which showed that the UK is a global leader in cell and gene therapy (CGT), with significant investment and the highest number of clinical trials in Europe.
Life Science 52
52 
2024 predictions: Experts comment on AI, ML and automation
Drug Discovery World
FEBRUARY 12, 2024
“In the upcoming year, we will see the expansion of new, more complex markets and updated requirements from regulators. Without fixing the current, broken PV models, the continuous cycle of more complexity in the market, which then pushes organisations to incorporate automation into insufficient processes, will massively hinder PV operations.
Genome 139
139 
Solid Biosciences acquires AavantiBio, conducts $75 million private placement
pharmaphorum
OCTOBER 4, 2022
The life sciences company Solid Biosciences is merging with the privately-held gene therapy company AavantiBio in a deal which is expected to result in a combined sum of $215 million in cash and investments – projected to be enough for funding into 2025. This is due to close concurrently with the merger.
Gene Therapy 108
108 
Let's personalize your content